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Background: Mesenchymal stem cells (MSCs) are multipotent stem cells able to differentiate into different cell
lineages. However, MSCs represent a subpopulation of a more complex cell composition of stroma cells contained
in mesenchymal tissue. Due to a lack of specific markers, it is difficult to distinguish MSCs from other more mature
stromal cells such as fibroblasts, which, conversely, are abundant in mesenchymal tissue. In order to find more
distinguishing features between MSCs and fibroblasts, we studied the phenotypic and functional features of
human adipose-derived MSCs (AD-MSCs) side by side with normal human dermal fibroblasts (HNDFs) in vitro
Methods: AD-MSCs and HNDFs were cultured, expanded and phenotypically characterized by flow cytometry (FC).
Immunofluorescence was used to investigate cell differentiation. ELISA assay was used to quantify angiogenic
factors and chemokines release. Cultures of endothelial cells (ECs) and a monocyte cell line, U937, were used to
test angiogenic and anti-inflammatory properties.
Results: Cultured AD-MSCs and HNDFs display similar morphological appearance, growth rate, and phenotypic
profile. They both expressed typical mesenchymal markers-CD90, CD29, CD44, CD105 and to a minor extent, the
adhesion molecules CD54, CD56, CD106 and CD166. They were negative for the stem cell markers CD34, CD146,
CD133, CD117. Only aldehyde dehydrogenase (ALDH) was expressed. Neither AD-MSCs nor HNDFs differed in their
multi-lineage differentiation capacity; they both differentiated into osteoblast, adipocyte, and also into
cardiomyocyte-like cells. In contrast, AD-MSCs, but not HNDFs, displayed strong angiogenic and anti-inflammatory
activity. AD-MSCs released significant amounts of VEGF, HGF and Angiopoietins and their conditioned medium
(CM) stimulated ECs proliferation and tube formations. In addition, CM-derived AD-MSCs (AD-MSCs-CM) inhibited
adhesion molecules expression on U937 and release of RANTES and MCP-1. Finally, after priming with TNFa, AD-
MSCs enhanced their anti-inflammatory potential; while HNDFs acquired pro-inflammatory activity.
Conclusions: AD-MSCs cannot be distinguished from HNDFs in vitro by evaluating their phenotypic profile or
differentiation potential, but only through the analysis of their anti-inflammatory and angiogenic properties. These
results underline the importance of evaluating the angiogenic and anti-inflammatory features of MSCs preparation.
Their priming with inflammatory cytokines prior to transplantation may improve their efficacy in cell-based
therapies for tissue regeneration.
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Within the panorama of adult stem cells, mesenchymal
stem cells (MSCs) have been proposed for application in
cell-based therapies because of their multipotential differ-
entiation capacity, easy tissue accessibility and capacity
for ex-vivo expansion [1]. MSCs are localized in the
stroma of tissue or organs, and they have been isolated
and characterized from different adult tissue sources
such as bone marrow (BM), skeletal muscle, pancreas,
vessels, dental pulp and adipose tissue [2-7]. Different
methods for their isolation and culture expansion have
been described [3,4,8]. The majority of techniques used
direct adhesion to tissue culture plastic to separate MSCs
from the unwanted cells contained in the stroma [5,8].
This procedure can be easily applied to separate MSCs
from BM or umbilical cord blood. In fact, unwanted cells
continue to float in the culture medium and can be easily
discarded by replacing the culture medium. The techni-
que to separate MSCs from not-hematopoietic tissue, for
example adipose tissue, is more complex because MSCs
are only a small cell subpopulation of the total stromal
cells that adhere to plastic after seeding. In particular,
fibroblasts are adherent proliferating cells which are diffi-
cult to remove because they can survive and grow even
under extremely selective culture conditions.
Fibroblasts are considered mature mesenchymal cells
that are particularly abundant in the connective of each
organ and tissue. Therefore, these cells are the most fre-
quent contaminating cell phenotype present in many
cell culture systems [9]. Not only is it difficult to apply
techniques which successfully eliminate fibroblasts from
a culture, it is also particularly complex to distinguish
MSCs from fibroblasts in the same culture. Fibroblasts
and MSCs have an extremely similar morphological
appearance [10]; they both proliferate well and have
many identical cell surface markers [10]. MSCs lack a
specific surface antigen that precisely differentiates these
cells from fibroblasts. Stro-1, and more recently CD146,
have been claimed as specific markers for MSCs [11-13
]. However, these markers seem limited to MSCs
derived from BM (BM-MSCs) or from renal tissue, since
adipose-derived MSCs (AD-MSCs), for example, did not
display these markers [14,15]. In spite of these differ-
ences, MSCs of different tissue origin possess a very
similar phenotypic profile. They usually express high
levels of mesenchymal markers and in general do not
express hematopoietic markers [14,15]. Until now, the
best way to distinguish MSCs from fibroblasts is based
on the analysis of the functional properties of these two
kinds of cells; MSCs self-renew and retain multipotent
differentiation capacity, while fibroblasts seem more lim-
ited in both these functional properties [14]. However, a
deeper comparative analysis between MSCs and fibro-
blasts is lacking. In particular, given the importance of
the application of AD-MSCs in cell based therapies, it is
relevant to distinguish them from fibroblasts which sig-
nificantly contribute to the stromal cell population of
adipose tissue. In order to fill this gap and to find func-
tional features that may better help to distinguish cul-
ture of AD-MSCs from fibroblasts, in the present work
we investigated the phenotypic and functional properties
of three different preparations of human AD-MSCs and
two normal human dermal fibroblast (HNDFs) cell lines
side by side. We confirm that HNDFs and AD-MSCs
display similar phenotypic and functional features,
including the capacity to differentiate into different cell
l i n e a g e s .W eh e r ed e m o n s t r a t ef o rt h ef i r s tt i m et h a t ,
while AD-MSCs possess a strong anti-inflammatory and
angiogenic potential, HNDFs do not.
Methods
Isolation and culture of human AD-MSCs and Fibroblasts
Human fat specimens were excised from 3 patients after
approval by the ethics committee of “MIULLI” General
Regional Hospital (Acquaviva, Bari). Informed consent
was obtained from each human donor. Adipose tissue
samples were collected under sterile conditions from 3
male donors (aged from 40 and 60 years) who under-
went standard laparoscopic surgery (uncomplicated
colecistectomy and inguinal hernia), after a negative
blood screening for HIV, HBV, HCV, Treponema palli-
dum, HTLV-I and II. Each adipose tissue sample was
treated and cultured separately.
Human AD-MSCs were isolated as described [3,15].
Briefly, sterile adipose tissue samples were transferred in
50 ml falcon tubes containing PBS plus penicillin-strep-
tomicine solution and quickly transferred at 4°C tem-
perature to our laboratories. Each sample was repeatedly
washed with PBS for blood residual and connective tissue
removal. Subsequently, fat specimens were minced with
scissors and washed with PBS by centrifugation at 250 ×
g. After liquid phase removal, collagenase solution (0,25%
w / v )( S I G M AS t .L o u i s ,M o ,U S A )p l u s2 0 0μlD N A a s e
( S I G M A )a t1 : 1 0 0d i l u t i o nw e r ea d d e dt op e l l e t s .A l l
tubes were then incubated at 37°C for 2 hours. After
enzymatic digestion, cells were washed by centrifugation
at 250 × g for 10’. The pellets were resuspended in
DMEM +10% FBS medium, filtered (100 μmØ )t o
remove undigested tissue, seeded into T 25 culture flasks
and incubated at 37°C in a humidified atmosphere con-
taining 5% CO2. The following day, the medium was
aspirated and the adherent AD-MSCs were cultured in
EGM medium supplemented with 10% FCS, 50 ng/ml
bFGF and antibiotics (Lonza, Verviers, Belgium). The
two normal human adult dermal fibroblasts (HNDFs) cell
lines were purchased from Lonza (Verviers, Belgium cat-
alogue N° CC25) and cultured under identical conditions
used for AD-MSCs. Cultures were routinely passed at
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not expanded for more than 8-10 in vitro passages. The
growth rate of each AD-MSCs preparation and for
HNDFs was determined as previously described [15].
Briefly, AD-MSCs and HNDFs (at passage 4) were har-
vested from the culture flask by treatment with trypsin
(Sigma) in PBS (0.05% w/v). Following enzyme inactiva-
tion and centrifugation, cells were resuspended in EGM
+10% FCS and 50 ng/ml bFGF and seeded at a final den-
sity of 2 × 10
4 cells/ml in T25 culture flasks. After a 7-
day incubation, AD-MSCs and HNDFs were detached
and counted by hemocytometer.
Characterization of humanAD-MSCs and HNDFs
Cultures of AD-MSCs and HNDFs were characterized
by flow cytometry (FC). After trypsinization, cells were
resuspended with FC buffer (pH 7.2 PBS, BSA 0.5%,
Sodium Azide 0.02%) and fixed with paraformaldehyde
2%. AD-MSCs and HNDFs were marked at concentra-
tion of 1 × 10
5/500 μl. For phenotypic analysis, fluores-
cein isothiocyanate (FITC-F), phycoerythrin (PE) or
phycoerythrin-cyanin PC5 conjugate-antibodies were
used. The expression of the following markers were
investigated: CD44F, CD90PE, CD34PE, CD45F, CD54F,
CD146PE, CD117PC5, CD31F, vWf-F, CD105PE,
CD106PE, CD166F, CD40F, CD80F, CD86PE, FAS
(CD95 member of the family of TNFa’s receptors),
FAS-L (CD178 ligand of FAS) (Immunotech
®,M i l a n ,
Italy), CD56PE (Serotec
®, Italy), HLAIF, HLAIIPE,
CD29PE, CD49dPE (Biolegend
®, Italy), Stro-1PE (R&D
®,
Milan, Italy), CD133 (Miltenyi Biotec
®, Bologna, Italy).
AD-MSCs and HNDFs were incubated for 20’/room
temperature in a dark room and then cells were washed
with FC buffer to remove not-conjugated antibodies.
Epics “XL-MCL” (Beckman Coulter USA) flow cyt-
ometer was used for simultaneous forward (FSC) and
side scatter (SSC) measuring, and analyzing the multi-
parametric fluorescent phenotypic marker signals.
20,000 events were acquired for each analysis. Sample
histogram elaboration was performed with EXPO 32
software to assess fluorescent distribution.
Aldefluor test (Aldagen, Inc., North Carolina, USA)
was used to identify, evaluate, and isolate cells with low
side scatter which expressed high levels of aldehyde
dehydrogenase (ALDH). ALDH cells have been shown
to have properties of stem and progenitor cells [16].
The cellular samples were adjusted to a concentration
o f1×1 0
6 cells/ml with Assay Buffer provided in the
kit. The adjusted cell suspension was placed into each
“test” sample tube.
DEAB (diethylaminobenzaldehyde) solution, provided in
the kit, was added to the “control” tube. The samples were
incubated for 40’ at 37°C in the dark. Following incuba-
tion, the tubes were centrifuged for 5’ at 250 × g. The
pellets were suspended in 0.5 ml of Aldefluor Assay Buffer
provided by the kit and analyzed immediately by FC.
Differentiation of AD-MSCs and NHDFs
To examine the capacity of AD-MSCs and HNDFs to
differentiate toward adipogenic, osteogenic and cardio-
myogenic cell lineages, lineage-specific induction factors
were used. For osteogenic differentiation, AD-MSCs and
HNDFs were cultured in the presence of DMEM/F-12
supplemented with 10% FBS, 0.1 mM dexamethasone
(Sigma), 10 mM b-glycerolphosphate (Sigma) and 50
mM ascorbic acid (Sigma) for around 2 weeks. At the
end of incubation, osteogenic differentiation was
assessed by alkaline phosphatase (AP) expression (Milte-
nyi Biotec
®). Fully differentiated osteoblast-like cells
generated from AD-MSCs and HNDFs changed their
original fibroblastic shape into a cubical/epithelial shape
with prominent cytoplasmic extensions similar to an
osteblast morphology. Cells stained for AP activity with
NBT substrate appeared purple in color. Adipogenic dif-
ferentiation was obtained upon cultivation of AD-MSCs
and HNDFs in DMEM supplemented with 10% FBS, 1
mM dexamethasone (Sigma), 0.5 mM methyl-isobutyl-
xanthine (Sigma), 10 mg/ml insulin (Invitrogen, Carls-
bad, CA) and 100 mM indomethacin (Sigma) for 3
weeks. At the end of incubation, adipogenic-like cells
were revealed by staining with Oil Red O (Sigma).
Moreover, to confirm adipogenic differentiation, we ana-
lyzed the production of Adiponectin by HNDFs and
AD-MSCs by FC using anti-Adiponectin antibodies
(Sigma). Cardiomyogenic differentiation of AD-MSCs
and HNDFs was assessed by immunofluorescent assay
by testing the expression of anti-Desmin (Signa), anti-
Troponin C-cardiac (TNP-C), anti-Myocardial actin
(MyoA), anti-Connexin 43 (Cx43) and anti-Atrial
Natriuretic factor, all purchased from Biodesign Interna-
tional (Saco, ME, USA). Cardiomyogenic markers
expression on AD-MSCs and HNDFs was analyzed
upon 3 weeks of culture in EGM complete medium in
t h ep r e s e n c eo ri nt h ea b s e n c eo f1μ/ml 5-azacytidine
(Sigma) as previously described [15]. Briefly, after wash-
ing, the cells were incubated with secondary antibodies
Beckman Coulter FITC-conjugated Goat anti Mouse-
IgG (Immunotech
®, Milan, Italy) for 2 hours at room
temperature. Then the cells were washed to remove
excess antibodies. In order to stain the nuclei, samples
were incubated with DAPI (dilution 1:10,000 in PBS,
Sigma) for 8’ at room temperature. As negative controls,
irrelevant isotype-matched antibodies were used. The
slides were then mounted in Gel Mount (Biomedia, Fos-
ter City, CA) and sealed. Fluorescence analysis was
established with fluorescence inverted microscope Leica
DM IL (Leica Microsystems GmbH, Wetzlar, Germany).
The images were adjusted in contrast and brightness
Blasi et al. Vascular Cell 2011, 3:5
http://www.vascularcell.com/content/3/1/5
Page 3 of 14with the image processing module “Ambient LAS” for
the acquisition and overlay of fluorescent images (Leica
Microsystems GmbH, Wetzlar, Germany).
Evaluation of Growth factors and cytokines production by
AD-MSCs and HNDFs
ELISA-tests were performed to detect growth factors
and cytokines released by AD-MSCs and HNDFs in the
culture medium. Aliquots (2 ml) of conditioned medium
(CM) from AD-MSCs (AD-MSCs-CM) and HNDFs
(HNDFs-CM) cultures were collected after 72 hours at
70-80% of cell confluence and between 5-8 in vitro pas-
sages. Afterwards, AD-MSCs and HNDFs were detached
with trypsin, counted and stained with Trypan Blue to
detect cell viability and to normalize the amount of
released factors in respect to the number of cells.
The growth factors, Vascular Endothelial Growth Fac-
tor (VEGFa), Transforming Growth Factor b1 (TGF-b1),
Hepatocyte Growth Factor (HGF), Platelet-derived
Growth Factor (PDGF), Angiopoietin 1 (Ang-1) and 2
(Ang-2), IL6 and IL8 production were quantified with
ELISA-kits (R&D Systems, UK, Europe), according to
the manufacturer’s instructions.
The specific protein concentration in CMs was
detected in accordance with the standard guideline pro-
tocol supplied with ELISA kit. The background value of
each growth factor analyzed and contained in the con-
trol medium was subtracted. Absorbance was measured
at 450 nm with a microplates photometric reader
DV990BV4 (GDV, Italy).
Data were expressed as mean ± SD of the secreted
factor per 10
6 cells. Assay was repeated twice and each
sample was run in triplicate.
Evaluation of Angiogenic potential of AD-MSCs and
HNDFs
To assess the angiogenic potential of AD-MSCs and
HNDFs, we investigated the capacity of their CMs on the
proliferation of Human Umbilical Vein ECs (HUVECs)
(Lonza) and Human derma-derived microvascular ECs
(HMECs) isolated as previously described [17]. Both ECs
phenotypes were routinely maintained in EGM bullet kit
(Lonza) plus 10% FCS. ECs proliferation assay was per-
formed as described [17]. Briefly, HUVECs and HMECs
(at passage 3) were harvested from culture flasks by tryp-
sin. After enzyme inactivation and centrifugation, cells
were resuspended in EGM medium +0.2% BSA and
counted. To evaluate the growth response to AD-MSCs-
CM and HNDFs-CM, 0.5 ml of HUVECs and HMECs
(10
4 cells) were seeded into each well of a 24-multiwell
plate coated with collagen type I; after cell adhesion,
medium was aspirated and replaced with EGM complete
medium (+10% FCS + 50 ng/ml bFGF) supplemented or
not with different dilutions of CM. Positive control
growth medium consisted in EGM complete medium
plus 10 ng/ml of VEGFa (Lonza). After 72 h, the wells
were washed and the cells were fixed and stained. The
cells were counted with a calibrated ocular eyepiece in 10
different fields at 400× magnification. Every test was run
in triplicate, and at least 3 different CM preparations
were tested for both AD-MSCs and HNDFs.
To test the effect of AD-MSCs-CM and HNDFs-CM on
ECs tube formation, we used growth factor reduced-matri-
gel assay (Sigma) as described by Kleinman et al [18].
Briefly, around 50 ul of matrigel were seeded into cold
(maintained at 4°C) wells of a 96-multiwell plate. After
matrigel jellification at 37°C for 30’, HUVECs and HMECs
were seeded on matrigel at concentration of 10
4 cells/well
in 50 ul of EGM control growth medium diluted (1:1) or
not with AD-MSCs-CM and HNDFs-CM. On day 2 and 5
after seeding, the number of EC tube formations were
counted at 10× magnification by inverted microscopy and
reported as n° of tube structures/field.
Evaluation of anti-inflammatory activity of AD-MSCs and
NHDFs
The anti-inflammatory activity of AD-MSCs and HNDFs
was tested by applying AD-MSCs-CM and HNDFs-CM
on the U937 monocyte cell line (ATCC Manassas VA,
USA), both in the absence and the presence of inflam-
matory stimuli LPS 1 μg/ml (Sigma) and TNFa 25 ng/
ml (Sigma). The expression of the adhesion molecules
CD54, CD44, CD62L and CD49d on U937 were ana-
lyzed by FC. Briefly, U937 cells cultured in RPMI
(Sigma) +10% FCS were counted and diluted to a con-
centration of 2 × 10
5/ml. In a first series of experiments,
U937 were cultured in the presence or absence of differ-
ent dilutions of AD-MSCs-CM and HNDFs-CM for 24
hours. Afterwards, the cells were washed and pulsed
with TNFa 25 ng/ml for a further 12 hours. At the end
of incubations, U937 were treated, for 20’/room tem-
perature in dark room, with the different adhesion
molecules antibodies. After washing cells to remove not-
conjugated antibodies, adhesion molecules expression
was analyzed by FC. Using a similar procedure, we also
evaluated the adhesion molecules expression on AD-
MSCs and on HNDFs pulsed or not for 12 hours with
TNFa 25 ng/ml. ELISA-kits were used to quantify the
production of RANTES and MCP-1 (R&D Systems, UK,
Europe) by U937 under basal culture conditions, in the
presence of inflammatory stimuli (LPS 1 ug/ml and
TNFa 25 ng/ml) and in the presence of AD-MSCs-CM
and HNDFs-CM. Finally, we also evaluated the effect of
AD-MSCs-CM and HNDFs-CM on RANTES and MCP-
1 release by U937, after priming with TNFa.B r i e f l y ,
A D - M S C sa n dH N D F sw e r ee x p o s e df o r1 2h o u r st o
TNFa 25 ng/ml. Thereafter, cells were washed and
further incubated for 24 hours. At the end of
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U937 chemokines production. All the data were normal-
ized for 10
6 cells in 24 hours incubation. and the basal
level production of the same chemokines present in the
AD-MSCs-CM and in HNDFs-CM was subtracted.
Statistic analysis
Results are expressed as mean ± standard deviation
(SD). Statistical significance was evaluated by analysis of
variance followed by Tukey-Kramer multiple compari-
son test and by Student’st - t e s t .Apv a l u eo fl e s st h a n
0.05 denotes statistical significance.
Results
Culture of AD-MSCs and HNDFs showed a very similar
morphological appearance and phenotypic profile
AD-MSCs were isolated from subcutaneous fat speci-
mens obtained from 3 patients during the course of
abdominal surgery. AD-MSCs were cultured using EGM
medium supplemented with 10% FCS and bFGF. Suc-
cessful isolation and culture expansion of AD-MSCs
were obtained from all three specimens processed.
HNDF cell lines were maintained in vitro under the
same culture conditions of AD-MSCs. HNDFs and AD-
MSCs proliferated well in culture with an average dou-
bling time of 28-36 hrs and 38-46 hrs respectively. Cells
were usually plated in T25 culture flasks at a density of
20,000 cells/cm
2. Soon after culture, AD-MSCs showed
typical fibroblast-like morphology and did not display
any particular morphological differences when compared
to HNDFs, even upon 10 in vitro passages (Additional
file 1: Figure S1).
T h ep h e n o t y p i cp r o f i l eo fA D - M S C sa n dH N D F sw a s
determined by FC analysis and was performed upon 5
in vitro passages. At first, we analyzed the presence of
stem cell markers such as CD34, Stro-1, CD146, CD117,
CD133 and ALDH. As reported in Table 1, neither AD-
MSCs nor HNDFs expressed the stem cell markers
investigated, only ALDH was significantly expressed in
approximately 40% of the cells, but again, there was no
substantial difference between AD-MSCs and HNDFs
(Additional file 2: Figure S2)
In Table 1 all the results on the phenotypic characteri-
zation of HNDFs and AD-MSCs regarding mesenchy-
mal, endothelial and immunogenic markers (see also
Additional file 3: Figure S3) are summarized. The varia-
tion of each marker among the 3 different AD-MSC
preparations and the two HNDF cell lines analyzed was
less then 10%. Cells were almost 100% positive for
CD29, CD90, CD44 and CD105 mesenchymal markers,
and were practically negative for EC markers CD31 and
vWf. AD-MSCs and HNDFs had a very similar adhesion
molecules profile, showing a variable positivity for
markers such as CD166, CD54, CD106 and CD56.
Interestingly, only CD49d, an integrin involved in the
homing of cells to an inflammatory site [19], was signifi-
cantly more highly expressed on HNDFs compare to
AD-MSCs. Finally, the comparative analysis of markers
involved in immune response demonstrated again a
strong similarity between AD-MSCs and HNDFs. They
both expressed very low levels of CD80 and CD86 and
they lacked CD45 and HLA-II expression, while HLA-I
was present in 100% of the cells. Interestingly CD40, a
Table 1 Phenotypic characterization of human AD-MSCs
and HNDFs
AD-MSCs HNDFs
% of positive cells
(±SD)
% of positive cells
(± SD)
Stem cell markers
Stro-1 3.7 ± 3.2 5.5 ± 0.4
CD146 1.5 ± 1.0 1.2 ± 1.2
CD133 0.4 ± 0.3 absent
CD34 absent absent
CD117 0.1 ± 0.1 absent
ALDH 42 ± 8.3 41.0 ± 5.4
Mesenchymal
markers
CD105 98.4 ± 1.0 95.6 ± 2.2
CD90 97.6 ± 2.5 94.1 ± 3.2
CD44 92.5 ±3.6 97.1 ± 1.1
CD29 95.5 ± 2.0 91.1 ± 5-4
AM markers
CD166 66.1 ± 26.4 80.4 ± 5.8
CD106 25.2 ± 15.1 35.6 ± 7.8
CD54 19.6 ± 9.4 25.7 ± 15.5
CD56 17.8 ± 12.2 39.6 ± 5.6*






CD40 17,7 ± 5,9 84.1 ± 3.6**
CD80 4.6 ± 1.1 2.1 ± 0.9
CD86 2.6 ± 1.1 0.8 ± 0.7
CD45 absent absent
HLA-II 0.5 ± 0.5 1.1 ± 1.2
HLA-I 93.3 ± 3.3 94.0 ± 2.8
Table shows the phenotypic characterization of AD-MSCs and HNDFs in
culture. FACS analysis was performed when all cultures were at 5 in vitro
passages. Data represent the % of positive cells for each marker analyzed on
AD-MSCs and on HNDF and are means ± SD. Variability of each marker tested
among the different cell preparations were ≤ 10%. Note that some markers
such as CD56, CD49d and CD40 are more highly expressed in HNDFs when
compared to AD-MSCs. *p < 0.05 and **p < 0.01 compared to AD-MSCs.
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(APCs) [20], was more highly expressed on HNDFs, sug-
gesting a higher immunogenic profile of HNDFs if com-
pared with AD-MSCs. This data further confirms
previous results showing the positive expression of
CD40 on dermal fibroblasts [21]
AD-MSCs and HNDFs display similar differentiation
capacity
A typical feature of MSCs is their mutipotential differ-
entiation capacity [2,3]. Previous reports indicate that
MSCs of different tissue origin have the capacity to
differentiate into different cell lineages, while the mul-
tipotential differentiation capacity of fibroblasts is
more controversial [14]. Therefore, we compared the
capacity of AD-MSCs and HNDFs to differentiate into
different cell lineages. Under the same differentiation
culture conditions, AD-MSCs and HNDFs were
induced to differentiate into osteogenic, adipogenic
and cardiomyocyte-like cells. As shown in Figure 1,
AD-MSCs and HNDFs differentiate well into osteo-
blast-like and into adipocyte-like cells assessed by the
positivity to AP and Oil Red O staining respectively
(Figure 1A). To further confirm adipogenic differentia-
tion, AD-MSCs and HNDFs were also analyzed for
Adiponectin expression, a hormone specifically pro-
duced by mature adipocyte [22]. Upon adipogenic dif-
ferentiation, we found a similar significant increment
of Adiponectin expression in both AD-MSCs and
HNDFs (Additional file 4: Figure S4). They both differ-
entiated into cardiomyocyte-like cells, although a more
intense staining of MyoA, TNP-C and Desmin on AD-
MSCs was observed (Figure 1B). Other myocardial
markers, such as Cx43 and atrial natriuretic factor,
were not detected on either HNDFs or AD-MSCs
(data not shown).
Figure 1 AD-MSCs and HNDFs display similar capacity to differentiate into adipogenic, osteogenic and cardiomyogenic cell lineages.
The Figure shows the capacity of AD-MSCs and HNDFs to differentiate toward the adipogenic, osteogenic and cardiomyogenic cell lineages in
the presence of lineage-specific induction factors. In (A) is shown the positive staining of AD-MSCs and HNDFs for Oil Red O and AP, indicating
differentiation into adipogenic and osteogenic cell lineages respectively (magnification 20×). In (B) note the positive immunofluorescence
staining of AD-MSCs and HNDFs for Desmin, MyoA and TNP-C cardiomyogenic markers (magnification 10×).
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potential in vitro
To define the angiogenic activity of AD-MSCs and
HNDFs, we first analyzed the production of angiogenic
growth factors and cytokines in their CM. AD-MSCs
and HNDFs were cultured for 72 hours, CM was then
analyzed by ELISA for the presence of VEGFa, HGF,
TGFb1, Ang-1, Ang-2 and PDGF. AD-MSCs demon-
strated a great capacity to produce a broad spectrum of
angiogenic factors (Figure 2). In 72 hours of culture, 10
6
cells produced an extremely high level of the angiogenic
factors HGF and VEGFa. AD-MSCs produced also sig-
nificant amounts of TGFb1, Ang-1 and Ang-2 and, to a
minor extent, PDGF. Interestingly, HNDFs had a signifi-
cantly lower production of all the angiogenic factors
analyzed. Compared to AD-MSCs, VEGF, HGF and
Ang-1 production in HNDFs was significantly lower.
We also analyzed the production of angiogenic cyto-
kines, such as IL6 and IL8, which were produced in
good quantities by both kinds of mesenchymal cells
(Additional file 5: Figure S5).
The angiogenic capacity of AD-MSCs and HNDFs
was also evaluated on the proliferation of HUVECs
and HMECs. As shown in Figure 3, the addition of
AD-MSCs-CM, at all different dilutions tested,
enhanced growth of both HUVECs (Figure 3A) and
HMECs (Figure 3B). In contrast, the addition of differ-
ent dilutions of HNDFs-CM did not enhance the pro-
liferation of either HUVECs (Figure 3A) or HMECs
(Figure 3B). The capacity AD-MSCs and HNDFs to sti-
mulate angiogenesis was also tested in vitro by evaluat-
ing the formation of capillary-like structures on
matrigel. AD-MSCs-CM and HNDFs-CM were added
to HMECs cultured on matrigel, a matrix that induces































Figure 2 AD-MSCs, but not HNDFs, produce high levels of angiogenic factors. ELISA-tests were performed to detect VEGFa, TGF-b1, HGF,
PDGF, Ang-1 and Ang-2 angiogenic factors released by AD-MSCs and HNDFs in the CM. Note that AD-MSCs, compared to HNDFs, release very
high quantities of VEGFa, HGF and Ang-1. Data are the absolute values expressed as mean ± SD of the secreted factor per 10
6 cells after 72 hrs
of incubation. The background values of angiogenic factors contained in EGM control medium (supplemented with 10% FCS and 50 ng/ml
bFGF) were subtracted. Tests were run in triplicate and repeated twice. ** p < 0.01 versus HNDFs release.
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within 3-4 days of culture [18]. As shown in Figure 3C
and 3D, within 2 days, the presence of AD-MSCs-CM
in the control medium substantially triplicated (AD-
MSCs-CM 25 ± 17 versus HNDFs-CM 8 ± 6) the
number of HMECs tube formations. Moreover, com-
pared to HNDFs-CM, AD-MSCs-CM produced a sig-
nificant delay of capillary-like structures regression
(Figure 3C and 3D). The effect of AD-MSCs-CM on
HUVECs was similar (data not shown).
AD-MSCs, but not HNDFs, possess strong anti-
inflammatory activity in vitro
It has been shown that MSCs display anti-inflammatory
capacity [15,23,24]. We thus investigated whether AD-
MSCs and HNDFs may produce molecules with anti-
inflammatory activity by testing their CM on U937, a
human monocyte cell line, under basal culture condi-
tions or in the presence of TNFa inflammatory stimuli.
A ss h o w ni nF i g u r e4 ,t h ee x p r e s s i o no ft h ea d h e s i o n
molecules CD54, CD44, CD62L, CD49d on U937 was
not significantly affected by the addition of both AD-
MSCs-CM and HNDFs-CM to the basal control med-
ium. After stimulation of U937 with TNFa (25 ng/ml),
expression of CD54 (Figure 4A), CD44 (Figure 4B) and
CD62L (Figure 4C) was increased and the addition of
AD-MSCs-CM (at 1:1 dilution) was able to antagonize
the increment (Figure 4A, B and 4C). In contrast,
the addition of HNDFs-CM did not affect adhesion
molecules increment induced by TNFa;o n l yC D 5 4
expression was slightly reduced (Figure 4A). Neither
AD-MSCs-CM nor HNDFs-CM had any affect on
CD49d expression (Figure 4D).
We also investigated the effect of AD-MSCs-CM and
HNDFs-CM on CD11a and CD11b expression, adhesion
molecules that are involved in inflammatory cells migra-
tion [25]. Only AD-MSCs-CM, but not HNDFs-CM,
induced a slight decrement of CD11a and Cd11b
expression on U937 (Additional file 6: Figure S6). We
next investigated the capacity of AD-MSCs-CM and
HNDFs-CM to affect the release of RANTES and MCP-
1 inflammatory chemokines by U937, under basal cul-
ture conditions or in the presence of TNFa and LPS
stimuli. AD-MSCs and HNDFs, per se, released very lit-
tle amounts of both RANTES and MCP-1 (< 20 pg/ml
for each chemokine) (data not shown). However, as
s h o w ni nF i g u r e5 ,t h ea d d i t i o no fA D - M S C s - C Mt o
U937 culture greatly inhibited RANTES (Figure 5A) and
MCP-1 (Figure 5B) release in a dose dependent manner
either in the presence or absence of LPS (1 μg/ml)
inflammatory stimulation. By contrast, however, the
addition of HNDFs-CM at every dilution tested did not
( F i g u r e5 Aa n d5 B ) .T h ec a p a c i t yo fA D - M S C s - C Mt o
block RANTES and MCP-1 chemokines release was
even more potent if U937 was stimulated with TNFa
f o r1 2h o u r s( F i g u r e5 Ca n d5 D ) .F i n a l l y ,w ea s k e d
whether exposing AD-MSCs and HNDFs to the inflam-
matory cytokine TNFa m a yi n d u c ec h a n g e si nt h e i r
activity on U937 chemokines release. To this end, AD-
MSCs and HNDFs were primed for 12 hours with
TNFa (25 ng/ml), thereafter the medium was replaced
with fresh medium, and 24 hours later CM was recov-
ered and tested on U937 chemokines production. As
s h o w ni nF i g u r e6 ,T N F a primed-AD-MSCs-CM
(P-AD-MSCs-CM) added to U937 enhanced inhibition
of RANTES and MCP-1 release by U937, either in the
presence or absence of TNFa stimuli. Thus, priming
with TNFa improved anti-inflammatory activity of AD-
MSCs on U937 chemokines release. Interestingly, the
addition of TNFa primed-HNDFs-CM (P-HNDFs-CM)
produced, by contrast, a significant increment of chemo-
kines release by U937 (Figure 6), indicating that HNDFs,
under stimulation with TNFa, behave in an opposite
manner.
Figure 3 AD-MSC-CM possess a higher capacity to stimulate
HUVECs and HMECs proliferation and tube formations
compare to HNDFs-CM. The effect of AD-MSCs-CM and HNDFs-CM
on proliferation of HUVECs (A) and HMECs (B) was tested by adding
different dilutions to EGM control medium. As a positive growth
control, we used VEGFa 10 ng/ml. AD-MSCs-CM addition had a
great capacity to stimulate the proliferation of HMECs (B) and to a
minor extent HUVECs (A), while HNDFs-CM addition did not affect
ECs proliferation at any dilution tested. In (C) and in (D) are shown
the capacity of AD-MSCs-CM and HNDFs-CM to induce HMECs tube
formation respectively. AD-MSCs-CM and HNDFs-CM were added at
a ratio 1:1 with EGM control medium (Magnification 10×). Note that
AD-MSCs-CM not only increased HMECs tube formation on day 2,
but also delayed their regression on day 5. The columns in (A) and
(B) are mean ± SD of three independent experiments run in
triplicate. *p < 0.05 and **p < 0.01 versus CTRL.
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Among the different stem cell phenotypes, adult MSCs
represent an extremely valid cell option to apply to
regenerative therapies. Besides their capacity to differ-
entiate into many different cell lineages, including neural
cells [26], MSCs display immunosuppressive [27], anti-
inflammatory [15,23], anti-apoptotic [28] and angiogenic
activity [15,28]-all distinguishing features of cells with
potential regenerative properties [29]. In addition, MSCs
can be isolated from many different adult human tissues
[2-7]; in particular, BM and adipose tissue are suffi-
ciently rich in MSCs content. For this reason, MSCs
d e r i v e df r o mB Ma n da d i p o s et i s s u eh a v eb e e ni n v e s t i -
gated more deeply and have been found to show simila-
rities in terms of phenotypic profile, differentiation
potential and in vivo regenerative capacity [7].
Procedures for their extraction and culture expansion
have been fully described [2,3]. However, one of the
major unsolved problems is the purity of MSCs prepara-
tion to use for therapeutic purposes. In fact, because of
a lack of specific MSC markers, the presence of contam-
inating mature stromal cells, such as fibroblasts, cannot
be distinguished and quantified, particularly in a fresh
preparation or even in an expanded culture of AD-
MSCs. Data from Lennon et al indicate that human
BM-MSCs intentionally contaminated by dermal fibro-
blasts continue to elicit a positive osteochondrogenesis
both in vitro and in vivo [30]. However, since there are
very few comparative studies between AD-MSCs and
fibroblasts and because the grade of purity of AD-MSC
preparations may directly affect their in vivo efficacy









































































Figure 4 AD-MSCs, but not HNDFs, reduced expression of AMs on U937. AD-MSCs-CM and HNDFs-CM were tested on the adhesion
molecules expression of the U937 monocyte cell line stimulated or not with TNFa (25 ng/ml × 12 hrs). Mean Fluorescent Intensity (MFI) of each
marker expression was evaluated by FACS and values are the mean ± SD of independent experiments performed with 3 different preparations
of AD-MSCs-CM and HNDFs-CM. In (A) the expression of CD54/ICAM-1, (B) the expression of CD44, (C) the expression of CD42L/L-selectin and in
(D) the expression of CD49d/VLA-4. Note that, both AD-MSCs-CM and HNDFs-CM did not affect basal adhesion molecules expression on U937.
However, AD-MSCs-CM, but not HNDFs-CM (at 1:1), inhibited CD54/ICAM-1, CD44 and CD42L/L-selectin up-modulation produced by TNFa
stimuli. CD49d expression was not affected by either AD-MSCs-CM or HNDFs-CM. * p < 0.05 and **p < 0.01 versus CTRL.
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Page 9 of 14AD-MSCs are unique or whether they may share essen-
tial characteristics with fibroblasts. To this end, we com-
pared the phenotypic and functional features of AD-
MSCs and two dermal fibroblast cell lines. AD-MSCs
were prepared from three different human donors fol-
lowing a standard procedure [15]. In contrast, we
decided to use two commercial established fibroblast
cell lines, to reduce the presence of cross-contaminating
MSCs-like cells which could be present in fresh culture
of dermal fibroblasts [10]. Moreover, commercial cell
lines, are usually well characterized and composed of a
more homogenous cell population if compared to fresh
cell preparations. In fact, FC analysis of the two HNDF
cell lines used confirmed the high level of stromal cell
purity; cells were almost 100% positive for each
mesenchymal marker tested (Table 1). In this regard,
the analysis of the phenotypic profile confirms previous
publications that indicate the absence of distinguishing
markers in AD-MSCs and HNDFs [10,14]; they both
expressed typical MSCs markers, were negative for
endothelial and hematopoietic markers and even simi-
larly negative for many stem cell markers, in particular
Stro-1 and CD146, which are, by contrast, described on
BM-MSCs [11,13]. Only ALDH activity, a stemness
functional marker used for identification of stem cells
and progenitors [16], was similarly present on both AD-
MSCs and HNDFs. In this study, we also investigated
the presence of immunogenic cell surface molecules on
AD-MSCs and HNDFs. We found that CD54, CD80
a n dC D 8 6w e r es i m i l a r l ye x p r e s s e d ,b yc o n t r a s t ,C D 4 0 ,
a co-stimulatory protein found on APCs [20], was more
highly expressed only on HNDFs. These data suggest
that mature fibroblasts could have a higher immuno-
































































































































Figure 5 Addition of AD-MSCs-CM, but not HNDFs-CM, to U937 blocked production of RANTES and MCP-by U937. ELISA-kits were used
to quantify the production of RANTES and MCP-1 by U937 under basal culture conditions, in the presence of inflammatory stimuli LPS(1 μg/ml)
(A and B) and TNFa (25 ng/ml) (C and D) and in the presence of AD-MSCs-CM and HNDFs-CM. In (A) RANTES and in (B) MCP-1 production are
blocked in a dose dependent manner by the addition of AD-MSCs-CM but not by HNDFs-CM under basal or in the presence of LPS. Similarly, in
(C) RANTES and in (D) MCP-1 release is inhibited by the addition of AD-MSCs-CM to U937 stimulated or not with TNFa for 12 hrs. The columns
in the figure are mean ± SD of three independent experiments run in triplicate. *p < 0.05 and **p < 0.01 versus CTRL.
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CD14 and HLA-DR may not be sufficient to endow
AD-MSC with APC function. In this study, we did not
investigate the immunosopressive activity of AD-MSCs
and HNDFs, because publications have already well
described the immunosuppressive activity of both fibro-
blasts and MSCs [27,33].
We could not find any differences between AD-MSCs
and HNDFs regarding morphological appearance in cul-
ture, growth rate and, more interestingly, in multipotential
differentiation capacity. Hence our results are in contrast
with Wagner et al [14] but support the finding of Lorenz
et al who propose dermal fibroblasts for application in the
therapy of wound healing because of their multilineage
differentiation potential [10].
B e s i d e st h i sa s p e c t ,i no u ro pinion this study has dis-
closed important new insights into functional differences
between AD-MSCs and HNDFs. More specifically, it is
known that HNDFs play an important role in angiogen-
esis, providing the extracellular matrix molecules
necessary to support capillary morphognesis [34] and a
balance of pro-angiogenic and anti-angiogenic factors to
determine the final vascular density [35,36]. We did not
investigate the production of extracellular matrix proteins
produced by AD-MSCs and HNDFs in culture, but
instead, we studied both the content of angiogenic growth
factors, such as VEGFa, HGF, TGFb1, Ang-1 and Ang-2
and PDGF released in the CM and, concomitantly, their
activity on ECs proliferation and tube-like formations. We
demonstrated, for the first time, that AD-MSCs were
extremely more angiogenic then HNDFs. Indeed, if com-
pared to HNDFs-CM, the level, in particular of VEGFa,
HGF and Ang-1, was significantly higher in the AD-
MSCs-CM as was its capacity to stimulate ECs prolifera-
tion. This data is consistent with our [15] and other pre-
vious reports [29] indicating the strong angiogenic
potential of AD-MSCs and their potential use for the ther-
apy of ischemic diseases [15,29]. Vice-versa, HNDFs
appear less angiogenic. Although it is still under debate, if










































Figure 6 Priming of AD-MSCs and HNDFs with TNFa induce an opposite effect on RANTES and MCP-1 release by U937. AD-MSCs and
HNDFs were primed for 12 hrs with TNFa 25 ng/ml. Thereafter cells were washed and further incubated for 24 hrs. At the end of incubation,
CMs were collected from primed AD-MSCs (P-AD-MSCs-CM) and primed HNDFs (P-HNDFs-CM) and tested on U937 chemokines production.
Note that, while the addition of P-AD-MSCs-CM to U937 completely blocked RANTES and MCP-1 release, in an opposite manner, P-HNDFs-CM
improved their release. The columns in the figure are mean ± SD of two independent experiments run in triplicate. ° p < 0.05 and °° p < 0.01
versus HNDF-CM, *p < 0.05 and **p < 0.01 versus AD-MSCs-CM, + p < 0.05 and ++ p < 0.01 versus CTRL.
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of MSCs could be inversely related with their grade of
maturation, explaining, at least in part, the reason why
dermal fibroblasts are less efficient than MSCs in promot-
ing wound healing [37]. In addition AD-MSCs, but not
HNDFs, were able to improve and stabilize HMECs tube-
like formation, probably through their capacity to secrete
significant quantities of Ang-1, an agiogenic factor
involved in vascular morphogenesis [38]. This result
expands on previous observations proposing that MSCs
are different from fibroblasts and more similar to peri-
cytes, [39] also because MSCs and pericytes are located in
the wall of vasculature [6,40].
This study confirms the strong anti-inflammatory poten-
tial of AD-MSCs [15,23] and concomitantly highlights, for
the first time, that HNDFs lack this property. In our opi-
nion, this appears to be the most distinguishing feature
between AD-MSCs and HNDFs. AD-MSCs were able to
reduce adhesion molecules expression and inhibit the
U937 release of the inflammatory chemokines RANTES
and MCP-1, under different inflammatory stimuli. HNDFs
did not affect any of the inflammatory activities of U937
monocytes. More interestingly, our results disclose a little-
studied characteristic of AD-MSCs and HNDFs. Indeed,
we observed that, under inflammatory stimuli, AD-MSCs
and HNDFs behave in an opposite manner on U937 che-
mokines release. Upon priming with TNFa,A D - M S C s
increased their capacity to block the release of RANTES
and MCP-1, while HNDFs, by contrast, acquired pro-
inflammatory activity, enhancing chemokines release by
U937. To our knowledge, this is a new finding, that could
be used not only to clearly distinguish between AD-MSCs
and fibroblasts preparations, but also to improve MSCs
regenerative properties when applied to cell therapy of
ischemic diseases [41]. In addition, enhancing anti-inflam-
matory activity of MSCs may provide a better strategy to
affect diseases where inflammation plays an important role
in supporting progression.
Conclusions
This study shows evidence that AD-MSCs and HNDFs
share a number of similar phenotypic functional features,
including the capacity to differentiate into different cell
lineages. We demonstrate that, to distinguish AD-MSCs
and HDNFs cultures, it is necessary to evaluate their
angiogenic and, overall, their anti-inflammatory potential.
A D - M S C sa r es i g n i f i c a n t l ym o r ea n g i o g e n i ca n da n t i -
inflammatory than HNDFs. In addition, under stimula-
tion with TNFa, AD-MSCs and HNDFs behave in an
opposite manner: AD-MSCs improve anti-inflammatory
activity, while HNDFs enhance inflammation. All
together these data suggest that, before application in
cell-based therapy, preparations of MSCs require testing
for their angiogenic and anti-inflammatory capacity.
Priming them with inflammatory cytokines may be useful
for improving their therapeutic efficacy.
Additional material
Additional file 1: Figure S1 Morphological appearance of AD-MSCs
and HNDFs in culture. The Figure shows the culture of AD-MSCs and
HNDFs at early (P3) and at late (P10) in vitro passages. Note that AD-
MSCs as well as HNDFs have a similar fibrablastic-like morphology
(magnification 10×)
Additional file 2: Figure S2 AD-MSCs and HNDFs show a similar
ALDH expression. Aldefluor test was used to identify stem and
progenitor cells with low side scatter that expressed high levels of ALDH.
The Figure shows FC analysis of ALDH expression on both AD-MSCs and
HNDFs. Note that both kinds of cell culture contained a similar
percentage of ALDH positive cells.
Additional file 3: Figure S3 Marker’s expression of AD-MSCs and
HNDFs. Note the high expression of mesenchymal markers CD90, CD44,
CD105, CD73 and CD166 on both AD-MSCs and HNDF, whereas HNDFs
expressed higher levels of CD40 and CD49d.
Additional file 4: Figure S4 AD-MSCs and HNDFs produce high level
of Adiponectin after adipogenic differentiation. Adiponectin
expression was used to confirm adipogenic differentiation of AD-MSCs
and HNDFs. The figure shows the FC of Adiponectin expression before
and after adipogenic differentiation of AD-MSCs and HNDFs. Note that
both kinds of cell culture expressed high level of Adiponectin after
differentiation.
Additional file 5: Figure S5 AD-MSCs, and HNDFs, produce high
levels of IL6 and IL8. ELISA-tests were performed to detect IL6 and IL8
cytokines released by AD-MSCs and HNDFs in the CM. Note that both
AD-MSCs, and HNDFs, release a high quantity of IL6 and IL8. Data are
expressed as mean ± SD of the secreted factor per 10
6 cells after 72 hrs
of incubation. Tests were run in triplicate and repeated twice. The
background values contained in EGM control medium were subtracted
Additional file 6: Figure S6 AD-MSCs-CM, but not HNDFs-CM,
reduced expression of CD11a and CD11b on U937 monocytes. Note
that the addition of AD-MSCs-CM (1:1), but not HNDFS-CM, to
U937culture medium slightly reduced MFI of CD11a CD11b, particularly
upon stimulation with TNFa.
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cells; BM: bone marrow; BM-MSC s: bone marrow derived MSCs; CM:
conditioned medium; Cx43: Connexin 43; ECs: endothelial cells; FC: Flow
cytometry; HGF: Hepatocyte growth factor; HNDFs: Human normal dermal
fibroblasts; HNDFs-CM: conditioned medium-derived HNDF; HMECs: human
microvascular endothelial cells; HUVECs: human umbilical vein endothelial
cells; MSCs: mesenchymal stem cells; MyoA: myocardial actin; LPS:
lipopolisaccaride; P-AD-MSCs-CM: priming-derived AD-MSCs-CM; PDGF:
platelet derived growth factor; P-HNDFs-CM: priming-derived HNDFs-CM;
SMCs: smooth muscle cells; TGFβ1: transforming growth factor β1; TNFα:
tumor necrosis factor α; TNP-C: cardiac troponin; VEGF: vascular endothelial
growth factor; vWf: von Willebrand factor
Acknowledgements
We thank Dr Andrea Smith for checking the English of the manuscript.
This research was partially supported by Medestea Research Laboratories
and AIRC (Associazione Italiana per la Ricerca sul Cancro)
Project AIRC IG-9062 “Role of human mesenchymal stem cells in tumor
angiogenesis”.
Author details
1Medestea Research and Production Laboratories, Consorzio Carso, 70010
Valenzano, Bari, Italy.
2Cellular Neurobiology Laboratory, Department of
Blasi et al. Vascular Cell 2011, 3:5
http://www.vascularcell.com/content/3/1/5
Page 12 of 14Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute “Carlo
Besta”, 20133 Milan, Italy.
Authors’ contributions
All authors have read and approved the final manuscript. AB, CM designed
experiments, differentiation experiments, performed in vitro experiments on
U937, performed FACS analysis and ELISA assay. LB, MS Isolation and culture
AD-MSCs, immunofluorescent characterization. SEN, LC, SC, and GI
Performed experiments on ECs and Matrigel assay, isolation and culture of
HUVECs and HMECs, AS, EAP supervised the manuscript, GA conceived,
directed the study, and wrote the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 August 2010 Accepted: 8 February 2011
Published: 8 February 2011
References
1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential
of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-
Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S,
Lisberg A, Low WC, Largaespada DA, Verfaillie CM: Pluripotency of
mesenchymal stem cells derived from adult marrow. Nature 2002, 418:
D42-D49.
3. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC,
Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of
multipotent stem cells. Mol Biol Cell 2002, 13:4279-4295.
4. Hu Y, Liao L, Wang Q, Ma L, Ma G, Jiang X, Zhao RC: Isolation and
identification of mesenchymal stem cells from human fetal pancreas.
J Lab Clin Med 2003, 141:342-349.
5. Nakatsuka R, Nozaki T, Uemura Y, Matsuoka Y, Sasaki Y, Shinohara M,
Ohura K, Sonoda Y: 5-Aza-2’-deoxycytidine treatment induces skeletal
myogenic differentiation of mouse dental pulp stem cells. Arch Oral Biol
2010, 55:350-357.
6. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B,
Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM,
Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Péault B: A
perivascular origin for mesenchymal stem cells in multiple human
organs. Cell Stem Cell 2008, 3:301-313.
7. Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I:
Comparison of rat mesenchymal stem cells derived from bone marrow,
synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res 2007,
327:449-462.
8. Boquest AC, Shahdadfar A, Brinchmann JE, Collas P: Isolation of stromal
stem cells from human adipose tissue. Methods Mol Biol 2006,
325:35-46.
9. Linge C, Green MR, Brooks RF: A method for removal of fibroblasts from
human tissue culture system. Exp Cell Res 1989, 185:519-528.
10. Lorenz K, Sicker M, Schmelzer E, Rupf T, Salvetter J, Schulz-Siegmund M,
Bader A: Multilineage differentiation potential of human dermal skin-
derived fibroblasts. Exp Dermatol 2008, 17:925-932.
11. Gronthos S, Graves SE, Ohta S, Simmons PJ: The STRO-1+ fraction of adult
human bone marrow contains the osteogenic precursors. Blood 1994,
84:4164-4173.
12. Bruno S, Bussolati B, Grange C, Collino F, di Cantogno LV, Herrera MB,
Biancone L, Tetta C, Segoloni G, Camussi G: Isolation and characterization
of resident mesenchymal stem cells in human glomeruli. Stem Cells Dev
2009, 18:867-880.
13. Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M,
Fatica A, Negrini M, Peschle C, Valtieri M: Isolation and characterization of
CD146+ multipotent mesenchymal stromal cells. Exp Hematol 2008,
36:1035-1046.
14. Wagner W, Wein F, Seckinger A: Comparative characteristics of
mesenchymal stem cellsfrom human bone marrow, adipose tissue, and
umbilical cord blood. Exp Hematol 2005, 33:1402-1416.
15. De Siena R, Balducci L, Blasi A, Montanaro MG, Saldarelli M, Saponaro V,
Martino C, Logrieco G, Soleti A, Fiobellot S, Madeddu P, Rossi G, Ribatti D,
Crovace A, Cristini S, Invernici G, Parati EA, Alessandri G: Omentum-derived
stromal cells improve myocardial regeneration in pig post-infarcted
heart through a potent paracrine mechanism. Exp Cell Res 2010,
316:1804-1815.
16. Moreb JS: Aldehyde dehydrogenase as a marker for stem cells. Curr Stem
Cell Res Ther 2008, 3:237-246.
17. Alessandri G, Chirivi RG, Fiorentini S, Dossi R, Bonardelli S, Giulini SM,
Zanetta G, Landoni F, Graziotti PP, Turano A, Caruso A, Zardi L, Giavazzi R,
Bani MR: Phenotypic and functional characteristics of tumour-derived
microvascular endothelial cells. Clin Exp Metastasis 1999, 17:655-662.
18. Kleinman HK, Martin GR: Matrigel: basement membrane matrix with
biological activity. Semin Cancer Biol 2005, 15:378-386.
19. Steingen C, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W:
Characterization of key mechanisms in transmigration and invasion of
mesenchymal stem cells. J Mol Cell Cardiol 2008, 44:1072-1084.
20. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: Molecular
mechanism and function of CD40/CD40L engagement in the immune
system. Immunol Rev 2009, 229:152-172.
21. Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP:
CD40 expression by human fibroblasts. Clin Immunol Immunopathol 1995,
77:42-51.
22. Ukkola O, Santaniemi M: Adiponectin: a link between excess adiposity
and associated comorbidities? J Mol Med 2002, 80:696-702.
23. Tanaka F, Tominaga K, Ochi M, Tanigawa T, Watanabe T, Fujiwara Y, Ohta K,
Oshitani N, Higuchi K, Arakawa T: Exogenous administration of
mesenchymal stem cells ameliorates dextran sulfate sodium-induced
colitis via anti-inflammatory action in damaged tissue in rats. Life Sci
2008, 83:771-779.
24. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, Sensebé L,
Zhang Y, Gorin NC, Thierry D, Fouillard L: Identification of IL-10 and TGF-
beta transcripts involved in the inhibition of T-lymphocyte proliferation
during cell contact with human mesenchymal stem cells. Gene Expr 2007,
13:217-226.
25. Paulsson JM, Dadfar E, Held C, Jacobson SH, Lundahl J: In vivo
transmigrated monocytes from patients with stable coronary artery
disease have a reduced expression of CD11b. Clin Exp Immunol 2008,
153:196-204.
26. Jiang J, Lv Z, Gu Y, Li J, Xu L, Xu W, Lu J, Xu J: Adult rat mesenchymal
stem cells differentiate into neuronal-like phenotype and express a
variety of neuro-regulatory molecules in vitro. Neurosci Res 2010, 66:46-52.
27. Nasef A, Mathieu N, Chapel A, Frick J, François S, Mazurier C, Boutarfa A,
Bouchet S, Gorin NC, Thierry D, Fouillard L: Immunosuppressive effects of
mesenchymal stem cells: involvement of HLA-G. Transplantation 2007,
84:231-237.
28. Park KS, Kim YS, Kim JH, Choi B, Kim SH, Tan AH, Lee MS, Lee MK,
Kwon CH, Joh JW, Kim SJ, Kim KW: Trophic molecules derived from
human mesenchymal stem cells enhance survival, function, and
angiogenesis of isolated islets after transplantation. Transplantation 2010,
89:509-517.
29. Caplan AI: Why are MSCs therapeutic? New data: new insight. J Pathol
2009, 217:318-324.
30. Lennon DP, Haynesworth SE, Arm DM, Baber MA, Caplan AI: Dilution of
human mesenchymal stem cells with dermal fibroblasts and the effects
on in vitro and in vivo osteochondrogenesis. Dev Dyn 2000, 219:50-62.
31. Mosna F, Sensebé L, Krampera M: Human Bone-Marrow And Adipose
Tissue Mesenchymal Stem Cells: A User’s Guide. Stem Cells Dev 2010,
19:1449-1470.
32. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D:
Minimal criteria for defining multipotent mesenchymal stromal cells.
Cytotherapy 2006, 8:315-317.
33. Sarkhosh K, Tredget EE, Karami A, Uludag H, Iwashina T, Kilani RT,
Ghahary A: Immune cell proliferation is suppressed by the interferon-
gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts
populated in collagen gel (FPCG). J Cell Biochem 2003, 90:206-217.
34. Berthod F, Germain L, Tremblay N, Auger FAJ: Extracellular matrix
deposition by fibroblasts is necessary to promote capillary-like tube
formation in vitro. Cell Physiol 2006, 207:491-498.
35. Black AF, Berthod F, L’heureux N, Germain L, Auger FA: In vitro
reconstruction of a human capillary-like network in a tissue-engineered
skin equivalent. FASEB J 1998, 12:1331-1340.
36. Hudon V, Berthod F, Black AF, Damour O, Germain L, Auger FA: A tissue-
engineered endothelialized dermis to study the modulation of
Blasi et al. Vascular Cell 2011, 3:5
http://www.vascularcell.com/content/3/1/5
Page 13 of 14angiogenic and angiostatic molecules on capillary-like tube formation in
vitro. Br J Dermatol 2003, 148:1094-1104.
37. Wu Y, Wang J, Scott PG, Tredget EE: Bone marrow-derived stem cells in
wound healing: a review. Wound Repair Regen 2008, 16:582.
38. Thomas M, Augustin HG: The role of the Angiopoietins in vascular
morphogenesis. Angiogenesis 2009, 12:125-37.
39. Caplan AI: All MSCs are pericytes? Cell Stem Cell 2008, 3:229-230.
40. Covas DT, Panepucci RA, Fontes AM, Silva WA Jr, Orellana MD, Freitas MC,
Neder L, Santos AR, Peres LC, Jamur MC, Zago MA: Multipotent
mesenchymal stromal cells obtained from diverse human tissues share
functional properties and gene-expression profile with CD146+
perivascular cells and fibroblasts. Exp Hematol 2008, 36:642-654.
41. Kim YS, Park HJ, Hong MH, kang PM, Morgan JP, Jeong MH, Cho JG,
Park JC, Ahn Y: TNF-alfa enhances engraftment of mesenchymal stem
cells into infracted myocardium. Front Biosci 2009, 14:2845-2856.
doi:10.1186/2045-824X-3-5
Cite this article as: Blasi et al.: Dermal fibroblasts display similar
phenotypic and differentiation capacity to fat-derived mesenchymal
stem cells, but differ in anti-inflammatory and angiogenic potential.
Vascular Cell 2011 3:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Blasi et al. Vascular Cell 2011, 3:5
http://www.vascularcell.com/content/3/1/5
Page 14 of 14